Results 261 to 270 of about 3,328,268 (306)

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

New fibrinolytic agents for MI: as effective as current agents, but easier to administer.

Cleveland Clinic journal of medicine, 2004
Keith Ellis, S. Brener
semanticscholar   +1 more source

Platelet Function and Fibrinolytic Agents: Two Sides of a Coin?

The Cardiology, 2001
K. Callahan, A. Malinin, P. Gurbel, J. Alexander, C. Granger, V. Serebruany   +5 more
semanticscholar   +1 more source

Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents

Current Cardiology Reports, 2003
W. S. Schroeder, P. Gandhi
semanticscholar   +1 more source

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Recent progress in the treatment of cancer in children

Ca-A Cancer Journal for Clinicians, 2021
Theodore W Laetsch
exaly  

Thromboelastographic Study of Fibrinolytic Agents

Seminars in Thrombosis and Hemostasis, 2012
openaire   +2 more sources

Plasminogen Activator Inhibitor Type-1 (Part Two): Role for Failure of Thrombolytic Therapy. PAI-1 Resistance as a Potential Benefit for New Fibrinolytic Agents

Journal of Thrombosis and Thrombolysis, 2001
K. Huber
semanticscholar   +1 more source

Improving the outcome for children with cancer: Development of targeted new agents

Ca-A Cancer Journal for Clinicians, 2015
Peter C Adamson
exaly  

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Ca-A Cancer Journal for Clinicians, 2019
Stephanie Lheureux, Marsela Braunstein, Amit M Oza   +2 more
exaly